

Therapeutics Advisory Group Update - Issue 24 – July 2023

All recommendations discussed at the **July** TAG and D+TC meetings and ratified by the Planned Care and Medicines Management Working Group on behalf of the ICB – **July 2023**. Please share within your organisation as appropriate

Commissioning Summary

Formulary application - Upadacitinib (Rinvoq®) for ulcerative colitis as per TA856	<ul style="list-style-type: none"> Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care
Formulary application - Ozanimod (Zeposia®) for ulcerative colitis as per TA828	
Formulary application - Empagliflozin (Jardiance®) for Symptomatic chronic heart failure with reduced ejection fraction in adults TA773	<ul style="list-style-type: none"> AMBER - Level 0 - Prescribe the drug and perform basic level of monitoring To be added to dapagliflozin SCA
Formulary application - Eltrombopag (Revolade®) for treatment of aplastic anaemia	
Commissioning Review – Updated pathways for publishing	<ul style="list-style-type: none"> BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE
Commissioning Review – Covid-19 treatments	<ul style="list-style-type: none"> Diabetic Macular Oedema Wet Age-Related Macular Degeneration Psoriatic Arthritis Rheumatoid Arthritis
Prescribing Updates - GLP-1 medication	<ul style="list-style-type: none"> Current changes from NHS England to ICB commissioning were noted Pathways will be updated as appropriate
Policies, Procedures and Clinical Guidelines for publishing	<ul style="list-style-type: none"> National shortage expected to last until 2024 National guidance recently published Key messages for local management of patients will be noted in forthcoming N+W guidance
Netformulary Updates	<ul style="list-style-type: none"> Management and the Administration of Continuous Subcutaneous Drug Infusions using a Syringe Pump and associated anticipatory medicines Policy – Adults – May 2023 Self-Care Policy v1.3 June 2023
<ul style="list-style-type: none"> Currently working on central nervous system section and hope to make this live in the coming weeks Also starting to add Trust formularies Gastro section and primary care pathways under review <p>We have several sections live on Netformulary. If you have any formulary queries, please remember to check there first before emailing the generic inbox</p>	

Shared Care Updates

Updated Shared Care Agreements for publishing <ul style="list-style-type: none"> Denosumab for treatment of osteoporosis in post-menopausal women at increased risk of fractures Riluzole for patients with amyotrophic lateral sclerosis (ALS) 	Updates supported by the TAG Published on Netformulary and Knowledge Anglia
Shared Care Agreements for review <ul style="list-style-type: none"> Hydroxychloroquine (RMOC) 	New agreement in development

NICE Guidance – acknowledged by the TAG

[CG57 – Dec 2007, updated June 2023](#) - Atopic eczema in under 12s: diagnosis and management

[NG101 – July 2018, updated June 2023](#) - Early and locally advanced breast cancer: diagnosis and management

[NG192 – March 2021, updated June 2023](#) - Caesarean birth

NICE Technology Appraisals – ICB Commissioning Responsibility

TA902 – June 2023 - Dapagliflozin (Forxiga®) for treating chronic heart failure with preserved or mildly reduced ejection fraction	BLUE – NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available.
TA907 – June 2023 - Deucravacitinib (SOTYKTU®) for treating moderate to severe plaque psoriasis	
TA906 – July 2023 - Rimegepant for preventing migraine	
TA905 – June 2023 - Upadacitinib (Rinvoq®) for previously treated moderately to severely active Crohn's disease (30-day implementation)	RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care
TA900 – June 2023 - Tixagevimab plus cilgavimab (Evusheld®) for preventing COVID-19	Noted by the TAG

NICE Technology Appraisals – NHS England Commissioning Responsibility

TA891 – May 2023 - Ibrutinib (Imbruvica®) with venetoclax for untreated chronic lymphocytic leukaemia	RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care
TA893 – June 2023 - Brexucabtagene autoleucel (Tecartus®) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over	
TA895 – June 2023 - Axicabtagene ciloleucel (Yescarta®) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy	
TA896 – June 2023 - Bulevirtide (Hepcludex®) for treating chronic hepatitis D	
TA897 – June 2023 - Daratumumab (Darzalex®) with bortezomib and dexamethasone for previously treated multiple myeloma	
TA898 – June 2023 - Dabrafenib (Tafinlar®) plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer	
TA903 – June 2023 - Darolutamide (Nubeqa®) with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer	
TA904 – June 2023 - Pembrolizumab (Keytruda®) with lenvatinib for previously treated advanced or recurrent endometrial cancer	BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE
TA892 – May 2023 - Mosunetuzumab (Lunsumio®) for treating relapsed or refractory follicular lymphoma	
TA894 – June 2023 - Axicabtagene ciloleucel (Yescarta®) for treating relapsed or refractory follicular lymphoma	

NICE Technology Appraisals – Terminated Appraisals

TA899 – June 2023 - Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)	BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE
TA901 – June 2023 - Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)	

Next meeting - Wednesday 6th September 2023. Deadline for agenda submissions - Tuesday 29th August 2023